Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Universal Scientific Education and Research Network (USERN) Office, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Front Immunol. 2022 Dec 14;13:1075813. doi: 10.3389/fimmu.2022.1075813. eCollection 2022.
Autoimmune disease, caused by unwanted immune responses to self-antigens, affects millions of people each year and poses a great social and economic burden to individuals and communities. In the course of autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes mellitus, and multiple sclerosis, disturbances in the balance between the immune response against harmful agents and tolerance towards self-antigens lead to an immune response against self-tissues. In recent years, various regulatory immune cells have been identified. Disruptions in the quality, quantity, and function of these cells have been implicated in autoimmune disease development. Therefore, targeting or engineering these cells is a promising therapeutic for different autoimmune diseases. Regulatory T cells, regulatory B cells, regulatory dendritic cells, myeloid suppressor cells, and some subsets of innate lymphoid cells are arising as important players among this class of cells. Here, we review the roles of each suppressive cell type in the immune system during homeostasis and in the development of autoimmunity. Moreover, we discuss the current and future therapeutic potential of each one of these cell types for autoimmune diseases.
自身免疫性疾病是由针对自身抗原的异常免疫反应引起的,每年影响数百万人,给个人和社区带来了巨大的社会和经济负担。在包括类风湿性关节炎、系统性红斑狼疮、1 型糖尿病和多发性硬化症在内的自身免疫性疾病中,针对有害抗原的免疫反应与针对自身抗原的耐受性之间的平衡被打破,导致针对自身组织的免疫反应。近年来,已经鉴定出各种调节性免疫细胞。这些细胞的质量、数量和功能的紊乱与自身免疫性疾病的发展有关。因此,针对这些细胞进行靶向或工程改造是治疗不同自身免疫性疾病的一种有前途的方法。调节性 T 细胞、调节性 B 细胞、调节性树突状细胞、髓源性抑制细胞和一些先天淋巴细胞亚群在这类细胞中作为重要的参与者出现。在这里,我们回顾了每种抑制性细胞类型在免疫系统中的稳态和自身免疫发展中的作用。此外,我们还讨论了这些细胞类型中的每一种用于治疗自身免疫性疾病的当前和未来的治疗潜力。
Front Immunol. 2022
Nature. 2011-11-27
Curr Neurol Neurosci Rep. 2025-7-1
Psychopharmacol Bull. 2024-7-8
Autoimmun Rev. 2025-7-8
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2020-1-9
Front Drug Deliv. 2024-8-8
Chin J Cancer Res. 2025-6-30
Front Immunol. 2025-5-16
Mol Ther. 2025-3-5
Stem Cell Res Ther. 2022-3-7
Expert Opin Biol Ther. 2022-4
Mol Metab. 2022-2
Int Immunopharmacol. 2022-1